<>
According to a population-based analysis published by researchers at Karolinska Institutet, measuring estrogen receptor (ER) positivity in breast cancer as a continuous spectrum rather than a strict binary category could significantly improve treatment accuracy and prognosis discussions for patients.
Quick Facts: ER Positivity Spectrum
- The Shift: Moving away from standard 1% or 10% cutoff thresholds toward a multi-tier spectrum.
- The Data: A nationwide analysis of over 75,000 Swedish breast cancer patients diagnosed between 2007 and 2023.
- The Finding: Patients with low-to-moderate ER expression (up to 59%) experience significantly poorer survival rates and distinct biological profiles compared to strongly ER-positive cases.
Redefining Estrogen Receptor Classification in Sweden and Globally
Internationally, breast tumors where at least 1% of cells express the estrogen receptor are classified as ER-positive, while Sweden traditionally uses a 10% threshold.
Balazs Acs, an associate professor at the Department of Oncology-Pathology at Karolinska Institutet, points out that clinical practice frequently encounters growths situated between standard diagnostic cutoffs, arguing that breast cancer should be understood along a continuum instead of classifying it strictly as ER-positive or ER-negative.
To evaluate the clinical impact of these intermediate levels, researchers analyzed data from 75,211 women diagnosed with HER2-negative breast cancer in Sweden between 2007 and 2023, according to findings detailed in The Lancet Regional Health – Europe. The team categorized patients into five distinct groups based on the percentage of tumor cells expressing the estrogen receptor:
- ER-zero: 0%
- ER-low: 1–9%
- ER-mild: 10–29%
- ER-moderate: 30–59%
- ER-high: 60–100%
By comparing tumor characteristics, treatment patterns, and survival rates across these tiers alongside molecular data from nearly 4,800 tumors, the study mapped out distinct clinical outcomes for each segment of the spectrum.
Survival Disparities Across the ER Spectrum
The analysis revealed stark survival differences linked to the exact density of estrogen receptor expression. Women whose tumors displayed low or moderate levels of estrogen receptors—ranging up to 59%—faced notably poorer survival rates than patients whose tumors exceeded the 60% threshold.
According to the findings cited by Inside Precision Medicine, survival outcomes for patients in the ER-mild and ER-moderate groups were 59% and 31% worse, respectively, than those observed in the ER-high cohort. Furthermore, molecular and clinical profiling showed that tumors with 10% to 29% ER expression (ER-mild) behaved similarly to very low or completely ER-negative tumors.
Acs points out that patients categorized with ER-mild tumors experienced survival rates strikingly comparable to those diagnosed with ER-low or even ER-negative conditions.
These prognostic divergences persisted even after researchers adjusted for confounding clinical variables such as patient age, tumor stage, and administered treatments.
Did You Know?
Estrogen receptor-positive breast cancer accounts for as much as 80% of all breast cancer cases. Knowing the exact status helps clinicians determine whether a patient will respond to standard hormone-blocking therapies.
Tailoring Combination Therapies for Intermediate ER Levels
The granular classification model also sheds light on why certain patient subsets respond differently to conventional treatment regimens. Because tumors with mild-to-moderate ER levels share biological characteristics distinct from strongly positive cases, standard endocrine therapy alone may be insufficient.
The study data indicated that patients falling into the ER-mild and ER-moderate classifications derived substantial benefit from receiving a combination of chemotherapy alongside hormone therapy. Specifically, the addition of chemotherapy improved survival outcomes by 54% for the ER-mild group and 40% for the ER-moderate group.
"This suggests that the exact level of estrogen receptors may be important when choosing a treatment," explains Acs. Acs emphasizes that while existing classification systems depend heavily on one fixed cutoff point, their findings demonstrate that tumor biology shifts gradually rather than changing suddenly at any specific percentage.
Future Directions in Precision Oncology
While the nationwide registry study provides comprehensive observational data, researchers emphasize that treatments were not randomly allocated. Consequently, further clinical trials and validation studies are necessary to determine how continuous spectrum metrics can be formally integrated into routine diagnostic guidelines and treatment decision-making frameworks.
Future investigations by the Karolinska research team aim to explore underlying biological mechanisms driving the similarities between ER-low, ER-mild, and ER-negative tumors. Investigators also plan to evaluate the compounding prognostic role of additional secondary biomarkers, such as progesterone receptor expression.
Pro Tip for Clinicians and Researchers:
When reviewing pathology reports for HER2-negative breast cancer, tracking exact percentage ranges rather than relying solely on binary cutoffs can help identify patients who might benefit from expanded treatment combinations.
Frequently Asked Questions
What is the traditional threshold for ER-positive breast cancer?
Internationally, tumors are classified as ER-positive if at least 1% of tumor cells express the estrogen receptor, whereas Sweden historically utilized a 10% cutoff threshold.
Why do patients with moderate ER expression have different outcomes?
Data shows that tumors with 30% to 59% ER expression possess distinct biological characteristics and are associated with significantly poorer survival rates on standard hormone therapy alone compared to tumors with high (60%–100%) positivity.
Can combination therapy help patients with intermediate ER levels?
Yes. According to the study findings, patients with mild-to-moderate ER levels experienced improved survival when treated with a combination of chemotherapy and hormone therapy.
Are these findings practice-changing immediately?
The results stem from an observational study conducted in collaboration with Karolinska University Hospital. Researchers stress that further studies and clinical trials are required before updating standard global treatment guidelines.
Join the Discussion: What are your thoughts on shifting from binary diagnostic thresholds to a continuous spectrum model in oncology? Share your perspective in the comments below, or subscribe to our newsletter for ongoing updates in precision medicine.
Related reading